WO2012008711A2 - Erlotinib dichloroacetate and anti-cancer agent comprising the same - Google Patents
Erlotinib dichloroacetate and anti-cancer agent comprising the same Download PDFInfo
- Publication number
- WO2012008711A2 WO2012008711A2 PCT/KR2011/004985 KR2011004985W WO2012008711A2 WO 2012008711 A2 WO2012008711 A2 WO 2012008711A2 KR 2011004985 W KR2011004985 W KR 2011004985W WO 2012008711 A2 WO2012008711 A2 WO 2012008711A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- erlotinib
- dichloroacetate
- crystalline form
- cancer
- intensity
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to erlotinib dichloroacetate and an anti-cancer agent comprising the same. More particularly, the present invention relates to erlotinib dichloroacetate capable of inhibiting epidermal growth factor receptor as well as inducing cancer cells to kill themselves via apoptosis, thereby inhibiting growth of cancer cells and leading to their destruction, and showing significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid, and an anti-cancer agent comprising the same.
- Erlotinib is a generic name of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine of the following formula (II), which is described in U.S. Patent No. 5,747,498, which is incorporated in its entirety here by reference.
- Erlotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed at least one prior chemotherapy regimen, or in combination with gemcitabine for the treatment of locally advanced, unresectable or metastatic pancreatic cancer.
- NSCLC non-small cell lung cancer
- US Patent No. 6,900,221 which is incorporated in its entirety here by reference, discloses crystalline form A and crystalline form B of erlotinib hydrochloride of the following formula (III), and teaches that crystalline form B is thermodynamically more stable than crystalline form A.
- erlotinib is manufactured as erlotinib hydrochloride of the following formula (III), and is marketed in many countries under the trade name of TARCEVA.
- the pharmaceutically acceptable salts of erlotinib are particularly mentioned addition salts with an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, p-toluene sulfonic acid, benzoic acid, citric acid, tartaric acid, succinic acid, oxalic acid, benzene sulfonic acid, methane sulfonic acid, phosphoric acid and mixtures thereof.
- an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, p-toluene sulfonic acid, benzoic acid, citric acid, tartaric acid, succinic acid, oxalic acid, benzene sulfonic acid, methane sulfonic acid, phosphoric acid and mixtures thereof.
- erlotinib has been known as a useful anti-cancer drug to prolong a patient's life, it has not been reported that erlotinib alone can treat cancer completely. Further, erlotinib causes toleranace as other anti-cancer agents do, and has the side effects of edema, fatigue, anxiety, headache, depression, vertigo, insomnia, rash, pruritus, xeroderma, erythema, diarrhea, anorexia, nausea, emesis, mucositis, glossalgia, stomatitis, xerostomia, pain, constipation, dyspepsia, dysphagia, weight loss, abdominal pain, dysgensia, hyperbilirubinemia, arthralgia, paresthesia, conjunctivitis, keratoconjunctivitis sicca, dyspnea, cough, infection, etc. with high rate of at least 10%.
- Dichloroacetic acid is an acetic acid derivative in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms, and has activities of treating lactic acidosis and cancers.
- dichloroacetic acid is very corrosive and extremely destructive to tissues of the mucous membranes and upper respiratory tract, the salts of dichloroacetic acid such as sodium dichloroacetate and potassium dichloroacetate are therapeutically used.
- the salts of dichloroacetic acid have been used as drugs for treating lactic acidosis by inhibiting pyruvate dehydrogenase kinase and activating pyruvate dehydrogenase, which is described in Ann Intern Med 108 (1): 58 ⁇ 63 (1988), which is incorporated in its entirety here by reference.
- erlotinib dichloroacetate prepared from erlotinib and dichloroacetic acid having low toxicity and inducing cancer cells to kill themselves via apoptosis, can show significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid. Further, the inventors have found that erlotinib dichloroacetate can eliminate the difficulties in uniformly and completely mixing two ingredients in the same dosage unit in the case of the combination therapy.
- An object of the present invention is, therefore, to provide erlotinib dichloroacetate showing significantly enhanced anti-cancer effects.
- Another object of the present invention is to provide an anti-cancer agent comprising erlotinib dichloroacetate.
- the present invention relates to erlotinib dichloroacetate of the following formula (I).
- the erlotinib dichloroacetate according to one embodiment of the present invention is particularly a crystalline erlotinib dichloroacetate, more particularly, a crystalline erlotinib dichloroacetate (hereinafter "crystalline form I") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/I o values of at least 10% (I is the intensity of each peak; I o is the intensity of the highest peak) at diffraction angles (2 ⁇ ) of 6.6 ⁇ 0.2, 9.3 ⁇ 0.2, 13.1 ⁇ 0.2, 14.9 ⁇ 0.2, 18.5 ⁇ 0.2, 19.2 ⁇ 0.2, 20.1 ⁇ 0.2, 20.7 ⁇ 0.2, 21.1 ⁇ 0.2, 22.6 ⁇ 0.2, 22.9 ⁇ 0.2, 26.2 ⁇ 0.2, 26.4 ⁇ 0.2, 27.0 ⁇ 0.2, 28.2 ⁇ 0.2, and 28.5 ⁇ 0.2.
- XRPD X-ray powder diffraction
- the erlotinib dichloroacetate according to another embodiment of the present invention is a crystalline erlotinib dichloroacetate (hereinafter "crystalline form II") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/I o values of at least 10% (I is the intensity of each peak; I o is the intensity of the highest peak) at diffraction angles (2 ⁇ ) of 6.6 ⁇ 0.2, 8.0 ⁇ 0.2, 13.0 ⁇ 0.2, 16.0 ⁇ 0.2, 16.8 ⁇ 0.2, 20.4 ⁇ 0.2, 20.8 ⁇ 0.2, 21.6 ⁇ 0.2, 22.9 ⁇ 0.2, 23.4 ⁇ 0.2, 26.0 ⁇ 0.2, 26.5 ⁇ 0.2, 27.0 ⁇ 0.2, and 31.1 ⁇ 0.2.
- XRPD X-ray powder diffraction
- the erlotinib dichloroacetate according to further embodiment of the present invention is a crystalline erlotinib dichloroacetate (hereinafter "crystalline form III") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/I o values of at least 10% (I is the intensity of each peak; I o is the intensity of the highest peak) at diffraction angles (2 ⁇ ) of 7.6 ⁇ 0.2, 17.7 ⁇ 0.2, 18.2 ⁇ 0.2, 18.5 ⁇ 0.2, 21.7 ⁇ 0.2, 22.7 ⁇ 0.2, 23.2 ⁇ 0.2, 23.8 ⁇ 0.2, 26.6 ⁇ 0.2, and 29.1 ⁇ 0.2.
- XRPD X-ray powder diffraction
- the erlotinib dichloroacetate according to further embodiment of the present invention is a crystalline erlotinib dichloroacetate hydrate (hereinafter "crystalline form IV") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/I o values of at least 10% (I is the intensity of each peak; I o is the intensity of the highest peak) at diffraction angles (2 ⁇ ) of 7.2 ⁇ 0.2, 9.1 ⁇ 0.2, 14.6 ⁇ 0.2, 17.0 ⁇ 0.2, 18.0 ⁇ 0.2, 20.1 ⁇ 0.2, 20.9 ⁇ 0.2, 23.7 ⁇ 0.2, 25.9 ⁇ 0.2, 27.0 ⁇ 0.2, 28.0 ⁇ 0.2, 29.0 ⁇ 0.2, 32.0 ⁇ 0.2, and 32.9 ⁇ 0.2.
- XRPD X-ray powder diffraction
- the erlotinib dichloroacetate of the above formula (I) according to the present invention can be prepared by reacting erlotinib of the following formula (II) and dichloroacetic acid of the following formula (IV).
- the erlotinib dichloroacetate of the present invention can be prepared by dissolving erlotinib and dichloroacetic acid in an organic solvent, followed by stirring.
- the erlotinib dichloroacetate can be prepared by suspending erlotinib in an organic solvent and adding dichloroacetic acid to the resulting supspension, followed by stirring, or by dissolving erlotinib and dichloroacetic acid together in an organic solvent, followed by stirring.
- the dichloroacetic acid can be used in an amount of approximately 1 equivalent based on the amount of erlotinib.
- the process for preparing the erlotinib dichloroacetate of the present invention can further optionally include the step of:
- the organic solvent can include one or more selected from alcohols such as methanol, ethanol, isopropanol, 1-butanol and 1-hexanol; ethers such as tetrahydrofuran, dioxane, diethyl ether and diisopropyl ether; nitriles such as acetonitrile; ketones such as acetone and 2-butanone; esters such as ethyl acetate and isopropyl acetate; and chlorinated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane.
- alcohols such as methanol, ethanol, isopropanol, 1-butanol and 1-hexanol
- ethers such as tetrahydrofuran, dioxane, diethyl ether and diisopropyl ether
- nitriles such as acetonitrile
- ketones such as acetone and 2-butanone
- the precipitating solvent can include one or more selected from alcohols such as ethanol, isopropanol, 1-butanol and 1-hexanol; ethers such as tetrahydrofuran, dioxane, diethyl ether and diisopropyl ether; nitriles such as acetonitrile; ketones such as acetone and 2-butanone; hydrocarbons such as n-pentane and n-hexane; aromatic hydrocarbons such as benzene, toluene and xylene; esters such as ethyl acetate and isopropyl acetate; and chlorinated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane.
- alcohols such as ethanol, isopropanol, 1-butanol and 1-hexanol
- ethers such as tetrahydrofuran, dioxane, diethyl ether and diis
- the reaction time can be 1 to 5 hours, and the reaction temperature can be 20 to 60 °C.
- the process for preparing the erlotinib dichloroacetate can further include washing and drying the solid obtained after filtering.
- the present invention further relates to an anti-cancer agent comprising the erlotinib dichloroacetate together with a pharmaceutically acceptable carrier.
- the anti-cancer agent of the present invention can be used for treating non-small cell lung cancer (NSCLC) or pancreatic cancer.
- the anti-cancer agent of the present invention can optionally include biologically active substances, in addition to the erlotinib dichloroacetate.
- the anti-cancer agent according to the present invention can be formulated as tablets, capsules, granules, powders, emulsions, suspensions, syrups, etc.
- the above various forms of the anti-cancer agent can be prepared in a manner well known in the art using a pharmaceutically acceptable carrier(s) which are usually used for each form.
- the pharmaceutically acceptable carriers include excipient, filler, extender, binder, disintegrator, lubricant, preservative, antioxidant, isotonic agent, buffer, coating agent, sweetening agent, dissolvent, base, dispersing agent, wetting agent, suspending agent, stabilizer, colorant, flavoring agent, etc.
- the anti-cancer agent of the present invention can contain 1 to 90 wt%, particularly 3 to 50 wt% of the inventive erlotinib dichloroacetate depending on the form thereof.
- the particular dosage of the present anti-cancer agent can be varied with species of mammals including a human-being, administration route, body weight, gender, age, severity of disease, judgment of doctor, etc.
- administration route 0.5 to 10 mg of the active ingredient is administered per kg of body weight a day for oral use.
- the total daily dosage can be administered once or over several times depending on the severity of disease, judgment of doctor, etc.
- the erlotinib dichloroacetate of the present invention can inhibit epidermal growth factor receptor as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction. Further, the erlotinib dichloroacetate can increase anti-cancer effects by synergy between erlotinib and dichloroacetic acid. Still further, since the erlotinib dichloroacetate can have the same or higher clinical efficacy at a lower dosage due to the synergy effect, the side effects can be decreased.
- the erlotinib dichloroacetate in accordance with the present invention can eliminate the difficulties in uniformly and completely mixing erlotinib and dichloroacetic acid in the same dosage unit.
- the crystalline erlotinib dichloroacetate in accordance with the present invention has good moisture and thermal stability, and low hygroscopicity.
- the crystalline erlotinib dichloroacetate can be effectively used for preparing a pharmaceutical composition.
- the erlotinib dichloroacetate in accordance with the present invention can be effectively used for preparing an anti-cancer agent for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed at least one prior chemotherapy regimen, or in combination with gemcitabine for the treatment of locally advanced, unresectable or metastatic pancreatic cancer.
- NSCLC locally advanced or metastatic non-small cell lung cancer
- Fig. 1 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate (crystalline form I) obtained in Example 1.
- Fig. 2 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate (crystalline form I) obtained in Example 1.
- Fig. 3 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate (crystalline form II) obtained in Example 6.
- Fig. 4 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate (crystalline form II) obtained in Example 6.
- Fig. 5 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate (crystalline form III) obtained in Example 7.
- Fig. 6 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate (crystalline form III) obtained in Example 7.
- Fig. 7 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate hydrate (crystalline form IV) obtained in Example 8.
- XRPD X-ray powder diffraction
- Fig. 8 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate hydrate (crystalline form IV) obtained in Example 8.
- Fig. 9 is a diagram illustrating the absorbance values (%) for the human lung cancer NCI-H460 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the erlotinib dichloroacetate, erlotinib hydrochloride and dichloroacetic acid, respectively, based on 100% of the absorbance value for the control.
- Fig. 10 is a diagram illustrating the absorbance values (%) for the colon cancer SW620 L6 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the erlotinib dichloroacetate, erlotinib hydrochloride and dichloroacetic acid, respectively, based on 100% of the absorbance value for the control.
- the light yellow crystalline solid formed was filtered, washed with 10 ml of ethyl acetate and dried under vacuum at 60 °C for 20 hours to give 9.90 g of the target compound. The yield was 94.76%.
- the obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 1 and 2, respectively.
- the light yellow crystalline solid formed was filtered, washed with 10 ml of diisopropyl ether and dried under vacuum at 60 °C for 20 hours to give 4.77 g of the target compound. The yield was 91.22%.
- the light yellow crystalline solid formed was filtered, washed with 10 ml of diisopropyl ether and dried under vacuum at 60 °C for 20 hours to give 4.91 g of the target compound. The yield was 93.90%.
- the light yellow crystalline solid formed was filtered, washed with 5 ml of tetrahedrofuran and dried under vacuum at 60 °C for 20 hours to give 4.43 g of the target compound. The yield was 84.72%.
- the light yellow crystalline solid formed was filtered, washed with 5 ml of acetonitrile and dried under vacuum at 60 °C for 20 hours to give 4.76 g of the target compound. The yield was 91.03%.
- the light yellow crystalline solid formed was filtered, washed with 10 ml of isopropanol and dried under vacuum at 60 °C for 20 hours to give 4.99 g of the target compound.
- the yield was 95.43%.
- the obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 3 and 4, respectively.
- the light yellow crystalline solid formed was filtered, washed with 10 ml of ethanol and dried under vacuum at 60 °C for 20 hours to give 9.21 g of the target compound. The yield was 88.15%.
- the obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 5 and 6, respectively.
- the light yellow crystalline solid formed was filtered, washed with 10 ml of methanol and dried under vacuum at 60 °C for 20 hours to give 3.81 g of the target compound. The yield was 72.86%.
- the obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 7 and 8, respectively.
- Erlotinib hydrochloride (crystalline form B) was prepared in accordance with the process described in U.S. Patent Publication No. 2009-0131665, which is incorporated in its entirety here by reference.
- the light yellow crystalline solid formed was filtered and dried under vacuum at 60 °C for 20 hours to give 20.35 g of the target compound. The yield was 93.13%.
- the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II), erlotinib dichloroacetate (crystalline form III) and erlotinib dichloroacetate hydrate (crystalline form IV) obtained in Examples 1, 6, 7 and 8, respectively, have distinctively characteristic peaks in the X-ray powder diffraction (XRPD) patterns.
- the observed characteristic peaks shown in the XRPD patterns of Figs. 1, 3, 5 and 7 are listed in Tables 1, 2, 3 and 4, respectively, wherein ‘2 ⁇ ’ is diffraction angle, ‘d’ is interplanar spacing, and 'I/I 0 ' is relative intensity of the peak.
- the moisture and thermal stability of an active ingredient in a pharmaceutical composition is an important factor on the perspective of the production process and long-term storage of the pharmaceutical composition.
- the moisture and thermal stabilities of the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II), erlotinib dichloroacetate (crystalline form III) and erlotinib dichloroacetate hydrate (crystalline form IV) respectively obtained in Examples 1, 6, 7 and 8, and the erlotinib hydrochloride (crystalline form B) obtained in Comparative Example 1 were measured.
- each erlotinib acid addition salt was stored in a sealed state under an accelerated condition (a temperature of 40 °C and a relative humidity of 75 %), and after 0 (zero), 3, 7, 14 and 28 days, the remaining rate of the active ingredient was analyzed with high performance liquid chromatography (HPLC). The results are listed in Table 5.
- Table 5 Salts Initial 3 days 7 days 14 days 28 days Erlotinib hydrochloride (crystalline form B) 100 100.1 100.1 100.0 100.0 Erlotinib dichloroacetate (crystalline form I) 100 100.1 100.0 100.0 100.1 Erlotinib dichloroacetate (crystalline form II) 100 100.0 100.0 100.0 Erlotinib dichloroacetate (crystalline form III) 100 100.1 100.0 100.0 Erlotinib dichloroacetate (crystalline form IV) 100 100.0 100.0 100.0 99.9
- the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II), erlotinib dichloroacetate (crystalline form III) and erlotinib dichloroacetate hydrate (crystalline form IV) showed the same level of good stability even when exposed to the accelerated condition for 28 days, as compared with the known erlotinib hydrochloride (crystalline form B). Such a result suggests that the erlotinib dichloroacetate of the present invention has good chemical stability to be effectively used for preparing a pharmaceutical composition.
- each of the erlotinib dichloroacetate (crystalline form I), erlotinib hydrochloride (crystalline form B) and dichloroacetic acid was dissolved in dimethylsulfoxide (DMSO) to prepare 10 mM solution, and then 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M solutions were respectively prepared using serum free medium. 100 ⁇ l of each prepared solution was seeded to the wells and incubated at 37 °C for 48 hours.
- DMSO dimethylsulfoxide
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- Control shows the absorbance that was measured for serum free medium containing no drug.
- the absorbance values for the cells respectively treated with erlotinib dichloroacetate, erlotinib hydrochloride and dichloroacetic acid were measured and the mean of four values was calculated, as the results (%) are represented in Figs. 9 and 10.
- the absorbance values for the human lung cancer NCI-H460 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the erlotinib dichloroacetate were 68.27%, 71.08%, 79.08% and 82.12%, respectively, based on 100% of the absorbance value for the control.
- the absorbance values for the NCI-H460 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the erlotinib hydrochloride were 94.04%, 96.76%, 101.72% and 102.49%, respectively.
- the absorbance values for the NCI-H460 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the dichloroacetic acid were 83.99%, 85.04%, 86.76% and 88.08%, respectively.
- the absorbance values for the colon cancer SW620 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the erlotinib dichloroacetate were 75.54%, 81.14%, 91.65% and 96.26%, respectively, based on 100% of the absorbance value for the control.
- the absorbance values for the SW620 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the erlotinib hydrochloride were 97.14%, 97.24%, 98.81% and 103.11%, respectively.
- the absorbance values for the SW620 cells which were treated with 3 ⁇ M, 1 ⁇ M, 0.3 ⁇ M and 0.1 ⁇ M of the dichloroacetic acid were 99.78%, 101.02%, 100.01% and 104.01%, respectively.
- the erlotinib dichloroacetate of the present invention has stronger anti-cancer effects than the erlotinib hydrochloride and generates synergy by the addition of dichloroacetic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to erlotinib dichloroacetate and an anti-cancer agent comprising the same. The erlotinib dichloroacetate of the present invention can inhibit epidermal growth factor receptor as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction, and show significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid.
Description
The present invention relates to erlotinib dichloroacetate and an anti-cancer agent comprising the same. More particularly, the present invention relates to erlotinib dichloroacetate capable of inhibiting epidermal growth factor receptor as well as inducing cancer cells to kill themselves via apoptosis, thereby inhibiting growth of cancer cells and leading to their destruction, and showing significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid, and an anti-cancer agent comprising the same.
Erlotinib is a generic name of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine of the following formula (II), which is described in U.S. Patent No. 5,747,498, which is incorporated in its entirety here by reference.
Erlotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed at least one prior chemotherapy regimen, or in combination with gemcitabine for the treatment of locally advanced, unresectable or metastatic pancreatic cancer.
US Patent No. 6,900,221, which is incorporated in its entirety here by reference, discloses crystalline form A and crystalline form B of erlotinib hydrochloride of the following formula (III), and teaches that crystalline form B is thermodynamically more stable than crystalline form A. Particularly, erlotinib is manufactured as erlotinib hydrochloride of the following formula (III), and is marketed in many countries under the trade name of TARCEVA.
US Patent No. 6,706,721, which is incorporated in its entirety here by reference, discloses anhydrous and hydrate forms of erlotinib mesylate. Also, WO 2008/122776, which is incorporated in its entirety here by reference, describes a process for the preparation of erlotinib and its pharmaceutically acceptable salts. As the pharmaceutically acceptable salts of erlotinib are particularly mentioned addition salts with an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, p-toluene sulfonic acid, benzoic acid, citric acid, tartaric acid, succinic acid, oxalic acid, benzene sulfonic acid, methane sulfonic acid, phosphoric acid and mixtures thereof. However, physiochemical properties such as moisture and thermal stability and hygroscopicity of the acid addition salts of erlotinib have never been reported in the above patent documents.
Although erlotinib has been known as a useful anti-cancer drug to prolong a patient's life, it has not been reported that erlotinib alone can treat cancer completely. Further, erlotinib causes toleranace as other anti-cancer agents do, and has the side effects of edema, fatigue, anxiety, headache, depression, vertigo, insomnia, rash, pruritus, xeroderma, erythema, diarrhea, anorexia, nausea, emesis, mucositis, glossalgia, stomatitis, xerostomia, pain, constipation, dyspepsia, dysphagia, weight loss, abdominal pain, dysgensia, hyperbilirubinemia, arthralgia, paresthesia, conjunctivitis, keratoconjunctivitis sicca, dyspnea, cough, infection, etc. with high rate of at least 10%.
Therefore, a combined modality therapy administering erlotinib together with a complementary drug has been suggested to overcome the problems described above. However, the combined modality therapy also cannot destruct cancer cells completely, and has difficulties in completely and uniformly mixing two active ingredients in the same dosage unit.
Dichloroacetic acid is an acetic acid derivative in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms, and has activities of treating lactic acidosis and cancers. However, since dichloroacetic acid is very corrosive and extremely destructive to tissues of the mucous membranes and upper respiratory tract, the salts of dichloroacetic acid such as sodium dichloroacetate and potassium dichloroacetate are therapeutically used.
Particularly, the salts of dichloroacetic acid have been used as drugs for treating lactic acidosis by inhibiting pyruvate dehydrogenase kinase and activating pyruvate dehydrogenase, which is described in Ann Intern Med 108 (1): 58~63 (1988), which is incorporated in its entirety here by reference.
A recent study published in Cancer Cell 11 (1): 37~51 (2007), which is incorporated in its entirety here by reference, testing dichloroacetic acid on in vitro cancer cell lines and a rat model, found that dichloroacetic acid restored mitochondrial function, thus restoring apoptosis, killing cancer cells in vitro, and shrinking the tumors in the rats.
The present inventors have researched on erlotinib in order to improve the anti-cancer effects and to reduce the side effects described above, and found that erlotinib dichloroacetate, prepared from erlotinib and dichloroacetic acid having low toxicity and inducing cancer cells to kill themselves via apoptosis, can show significantly enhanced anti-cancer effects by synergy between erlotinib and dichloroacetic acid. Further, the inventors have found that erlotinib dichloroacetate can eliminate the difficulties in uniformly and completely mixing two ingredients in the same dosage unit in the case of the combination therapy.
An object of the present invention is, therefore, to provide erlotinib dichloroacetate showing significantly enhanced anti-cancer effects.
Another object of the present invention is to provide an anti-cancer agent comprising erlotinib dichloroacetate.
The present invention relates to erlotinib dichloroacetate of the following formula (I).
The erlotinib dichloroacetate according to one embodiment of the present invention is particularly a crystalline erlotinib dichloroacetate, more particularly, a crystalline erlotinib dichloroacetate (hereinafter "crystalline form I") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 6.6±0.2, 9.3±0.2, 13.1±0.2, 14.9±0.2, 18.5±0.2, 19.2±0.2, 20.1±0.2, 20.7±0.2, 21.1±0.2, 22.6±0.2, 22.9±0.2, 26.2±0.2, 26.4±0.2, 27.0±0.2, 28.2±0.2, and 28.5±0.2.
The erlotinib dichloroacetate according to another embodiment of the present invention is a crystalline erlotinib dichloroacetate (hereinafter "crystalline form II") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 6.6±0.2, 8.0±0.2, 13.0±0.2, 16.0±0.2, 16.8±0.2, 20.4±0.2, 20.8±0.2, 21.6±0.2, 22.9±0.2, 23.4±0.2, 26.0±0.2, 26.5±0.2, 27.0±0.2, and 31.1±0.2.
The erlotinib dichloroacetate according to further embodiment of the present invention is a crystalline erlotinib dichloroacetate (hereinafter "crystalline form III") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 7.6±0.2, 17.7±0.2, 18.2±0.2, 18.5±0.2, 21.7±0.2, 22.7±0.2, 23.2±0.2, 23.8±0.2, 26.6±0.2, and 29.1±0.2.
The erlotinib dichloroacetate according to further embodiment of the present invention is a crystalline erlotinib dichloroacetate hydrate (hereinafter "crystalline form IV") showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 7.2±0.2, 9.1±0.2, 14.6±0.2, 17.0±0.2, 18.0±0.2, 20.1±0.2, 20.9±0.2, 23.7±0.2, 25.9±0.2, 27.0±0.2, 28.0±0.2, 29.0±0.2, 32.0±0.2, and 32.9±0.2.
The erlotinib dichloroacetate of the above formula (I) according to the present invention can be prepared by reacting erlotinib of the following formula (II) and dichloroacetic acid of the following formula (IV).
The process for preparing the erlotinib dichloroacetate of the present invention is described in more detail below.
The erlotinib dichloroacetate of the present invention can be prepared by dissolving erlotinib and dichloroacetic acid in an organic solvent, followed by stirring. Particularly, the erlotinib dichloroacetate can be prepared by suspending erlotinib in an organic solvent and adding dichloroacetic acid to the resulting supspension, followed by stirring, or by dissolving erlotinib and dichloroacetic acid together in an organic solvent, followed by stirring.
In one embodiment, the dichloroacetic acid can be used in an amount of approximately 1 equivalent based on the amount of erlotinib.
In one embodiment, the process for preparing the erlotinib dichloroacetate of the present invention can further optionally include the step of:
(i) stirring the reaction solution and filtering the solid formed;
(ii) lowering the temperature of the reaction solution with stirring and filtering the solid formed;
(iii) adding a precipitating solvent to the reaction solution with stirring and filtering the solid formed; or
(iv) evaporating the reaction solution under reduced pressure, adding a precipitating solvent to the obtained residue with stirring, and filtering the solid formed.
In one embodiment, the organic solvent can include one or more selected from alcohols such as methanol, ethanol, isopropanol, 1-butanol and 1-hexanol; ethers such as tetrahydrofuran, dioxane, diethyl ether and diisopropyl ether; nitriles such as acetonitrile; ketones such as acetone and 2-butanone; esters such as ethyl acetate and isopropyl acetate; and chlorinated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane.
In one embodiment, the precipitating solvent can include one or more selected from alcohols such as ethanol, isopropanol, 1-butanol and 1-hexanol; ethers such as tetrahydrofuran, dioxane, diethyl ether and diisopropyl ether; nitriles such as acetonitrile; ketones such as acetone and 2-butanone; hydrocarbons such as n-pentane and n-hexane; aromatic hydrocarbons such as benzene, toluene and xylene; esters such as ethyl acetate and isopropyl acetate; and chlorinated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane.
In one embodiment, the reaction time can be 1 to 5 hours, and the reaction temperature can be 20 to 60 ℃.
In one embodiment, the process for preparing the erlotinib dichloroacetate can further include washing and drying the solid obtained after filtering.
The present invention further relates to an anti-cancer agent comprising the erlotinib dichloroacetate together with a pharmaceutically acceptable carrier. In particular, the anti-cancer agent of the present invention can be used for treating non-small cell lung cancer (NSCLC) or pancreatic cancer.
In one embodiment, the anti-cancer agent of the present invention can optionally include biologically active substances, in addition to the erlotinib dichloroacetate.
The anti-cancer agent according to the present invention can be formulated as tablets, capsules, granules, powders, emulsions, suspensions, syrups, etc. The above various forms of the anti-cancer agent can be prepared in a manner well known in the art using a pharmaceutically acceptable carrier(s) which are usually used for each form. Examples of the pharmaceutically acceptable carriers include excipient, filler, extender, binder, disintegrator, lubricant, preservative, antioxidant, isotonic agent, buffer, coating agent, sweetening agent, dissolvent, base, dispersing agent, wetting agent, suspending agent, stabilizer, colorant, flavoring agent, etc.
In one embodiment, the anti-cancer agent of the present invention can contain 1 to 90 wt%, particularly 3 to 50 wt% of the inventive erlotinib dichloroacetate depending on the form thereof.
The particular dosage of the present anti-cancer agent can be varied with species of mammals including a human-being, administration route, body weight, gender, age, severity of disease, judgment of doctor, etc. By way of example, 0.5 to 10 mg of the active ingredient is administered per kg of body weight a day for oral use. The total daily dosage can be administered once or over several times depending on the severity of disease, judgment of doctor, etc.
The erlotinib dichloroacetate of the present invention can inhibit epidermal growth factor receptor as well as induce cancer cells to kill themselves via apoptosis, thereby inhibit growth of cancer cells and lead to their destruction. Further, the erlotinib dichloroacetate can increase anti-cancer effects by synergy between erlotinib and dichloroacetic acid. Still further, since the erlotinib dichloroacetate can have the same or higher clinical efficacy at a lower dosage due to the synergy effect, the side effects can be decreased.
Also, the erlotinib dichloroacetate in accordance with the present invention can eliminate the difficulties in uniformly and completely mixing erlotinib and dichloroacetic acid in the same dosage unit.
Also, the crystalline erlotinib dichloroacetate in accordance with the present invention has good moisture and thermal stability, and low hygroscopicity. Thus, the crystalline erlotinib dichloroacetate can be effectively used for preparing a pharmaceutical composition.
Accordingly, the erlotinib dichloroacetate in accordance with the present invention can be effectively used for preparing an anti-cancer agent for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has failed at least one prior chemotherapy regimen, or in combination with gemcitabine for the treatment of locally advanced, unresectable or metastatic pancreatic cancer.
Fig. 1 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate (crystalline form I) obtained in Example 1.
Fig. 2 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate (crystalline form I) obtained in Example 1.
Fig. 3 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate (crystalline form II) obtained in Example 6.
Fig. 4 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate (crystalline form II) obtained in Example 6.
Fig. 5 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate (crystalline form III) obtained in Example 7.
Fig. 6 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate (crystalline form III) obtained in Example 7.
Fig. 7 is an X-ray powder diffraction (XRPD) pattern of the erlotinib dichloroacetate hydrate (crystalline form IV) obtained in Example 8.
Fig. 8 is a differential scanning calorimeter (DSC) thermogram of the erlotinib dichloroacetate hydrate (crystalline form IV) obtained in Example 8.
Fig. 9 is a diagram illustrating the absorbance values (%) for the human lung cancer NCI-H460 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the erlotinib dichloroacetate, erlotinib hydrochloride and dichloroacetic acid, respectively, based on 100% of the absorbance value for the control.
Fig. 10 is a diagram illustrating the absorbance values (%) for the colon cancer SW620 L6 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the erlotinib dichloroacetate, erlotinib hydrochloride and dichloroacetic acid, respectively, based on 100% of the absorbance value for the control.
The present invention is further illustrated by the following examples, which are not to be construed to limit the scope of the invention.
Example 1: Preparation of erlotinib dichloroacetate (crystalline form I)
7.87 g (20.00 mmol) of erlotinib was suspended in 40 ㎖ of ethyl acetate, and 1.66 ㎖ (20.00 mmol) of dichloroacetic acid was added dropwise. Then, the reaction solution was stirred for 1 hour at 20 to 25 ℃. After the compounds were completely dissolved in the reaction solution and a solid began to be formed, the reaction solution was further stirred for 2 hours at 20 to 25 ℃.
The light yellow crystalline solid formed was filtered, washed with 10 ㎖ of ethyl acetate and dried under vacuum at 60 ℃ for 20 hours to give 9.90 g of the target compound. The yield was 94.76%. The obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 1 and 2, respectively.
M.P.: 144-145 ℃
1H NMR (400MHz, DMSO-d6) : δ= 9.82 (brs, 1 H), 8.54 (s, 1 H), 7.92 (s, 1 H), 7.87 (s, 1 H), 7.83 (d, 1 H, J = 7.6 Hz), 7.39 (t, 1 H, J = 8.0 Hz), 7.23 (d, 1 H, J = 7.2 Hz), 7.22 (s, 1 H), 6.51 (s, 1 H), 4.27 ~ 4.24 (m, 4 H), 4.18(s, 1 H), 3.76 ~ 3.71 (m, 4 H), 3.34 (s, 3 H), 3.32(s, 3 H).
Example 2: Preparation of erlotinib dichloroacetate (crystalline form I)
3.94 g (10.01 mmol) of erlotinib was suspended in 50 ㎖ of chloroform, and 0.83 ㎖ (10.01 mmol) of dichloroacetic acid was added dropwise. Then, the reaction solution was stirred for 1 hour at 20 to 25 ℃. After the compounds were completely dissolved in the reaction solution, 65 ㎖ of diisopropyl ether was added dropwise and the reaction solution was further stirred for 1 hour at 20 to 25 ℃.
The light yellow crystalline solid formed was filtered, washed with 10 ㎖ of diisopropyl ether and dried under vacuum at 60 ℃ for 20 hours to give 4.77 g of the target compound. The yield was 91.22%.
Example 3: Preparation of erlotinib dichloroacetate (crystalline form I)
3.94 g (10.01 mmol) of erlotinib was suspended in 50 ㎖ of methanol, and 0.83 ml (10.01 mmol) of dichloroacetic acid was added dropwise. Then, the reaction solution was stirred for 1 hour at 20 to 25 ℃, and distilled under reduced pressure to be completely concentrated. 50 ㎖ of acetone was added to the residue, and 100 ㎖ of diisopropyl ether was added dropwise to the resulting solution. After a solid began to be formed, the reaction solution was cooled to 0 to 5 ℃ and further stirred for 2 hours.
The light yellow crystalline solid formed was filtered, washed with 10 ㎖ of diisopropyl ether and dried under vacuum at 60 ℃ for 20 hours to give 4.91 g of the target compound. The yield was 93.90%.
Example 4: Preparation of erlotinib dichloroacetate (crystalline form I)
3.94 g (10.01 mmol) of erlotinib was suspended in 10 ㎖ of tetrahydrofuran, and 0.83 ml (10.01 mmol) of dichloroacetic acid was added dropwise. Then, the reaction solution was stirred for 3 hours at 20 to 25 ℃.
The light yellow crystalline solid formed was filtered, washed with 5 ㎖ of tetrahedrofuran and dried under vacuum at 60 ℃ for 20 hours to give 4.43 g of the target compound. The yield was 84.72%.
Example 5: Preparation of erlotinib dichloroacetate (crystalline form I)
3.94 g (10.01 mmol) of erlotinib was suspended in 10 ㎖ of acetonitrile, and 0.83 ml (10.01 mmol) of dichloroacetic acid was added dropwise. Then, the reaction solution was stirred for 3 hours at 20 to 25 ℃.
The light yellow crystalline solid formed was filtered, washed with 5 ㎖ of acetonitrile and dried under vacuum at 60 ℃ for 20 hours to give 4.76 g of the target compound. The yield was 91.03%.
Example 6: Preparation of erlotinib dichloroacetate (crystalline form II)
3.94 g (10.01 mmol) of erlotinib was suspended in 10 ㎖ of isopropanol, and 0.83 ml (10.01 mmol) of dichloroacetic acid was added dropwise. Then, the reaction solution was stirred for 30 minutes at 20 to 25 ℃. After the compounds were completely dissolved in the reaction solution and a solid began to be formed, 65 ㎖ of isopropanol was added and the reaction solution was further stirred for 2 hours at 20 to 25 ℃.
The light yellow crystalline solid formed was filtered, washed with 10 ㎖ of isopropanol and dried under vacuum at 60 ℃ for 20 hours to give 4.99 g of the target compound. The yield was 95.43%. The obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 3 and 4, respectively.
M.P.: 140-142 ℃
Example 7: Preparation of erlotinib dichloroacetate (crystalline form III)
7.87 g (20.00 mmol) of erlotinib was suspended in 60 ㎖ of ethanol, and 1.66 ㎖ (20.00 mmol) of dichloroacetic acid was added dropwise. Then, the reaction solution was stirred for 30 minutes at 20 to 25 ℃. After the compounds were completely dissolved in the reaction solution and a solid began to be formed, 20 ㎖ of ethanol was added and the reaction solution was further stirred for 3 hours at 20 to 25 ℃.
The light yellow crystalline solid formed was filtered, washed with 10 ㎖ of ethanol and dried under vacuum at 60 ℃ for 20 hours to give 9.21 g of the target compound. The yield was 88.15%. The obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 5 and 6, respectively.
M.P.: 142-144 ℃
Example 8: Preparation of erlotinib dichloroacetate hydrate (crystalline form IV)
3.94 g (10.01 mmol) of erlotinib was suspended in 20 ㎖ of distilled water and 0.83 ml (10.01 mmol) of dichloroacetic acid was added dropwise. To the reaction solution was added 50 ㎖ of methanol. Then, the reaction solution was heated to 50 to 55 ℃ and stirred for 1 to 2 hours. After the compounds were completely dissolved in the reaction solution, the reaction solution was slowly cooled to 20 to 25 ℃ and further stirred for 2 hours.
The light yellow crystalline solid formed was filtered, washed with 10 ㎖ of methanol and dried under vacuum at 60 ℃ for 20 hours to give 3.81 g of the target compound. The yield was 72.86%. The obtained crystalline erlotinib dichloroacetate was subjected to X-ray powder diffraction (XRPD) and differential scanning calorimeter (DSC) analyses, and the results are shown in Figs. 7 and 8, respectively.
M.P.: 126-128 ℃
Comparative Example 1: Preparation of erlotinib hydrochloride (crystalline form B)
Erlotinib hydrochloride (crystalline form B) was prepared in accordance with the process described in U.S. Patent Publication No. 2009-0131665, which is incorporated in its entirety here by reference.
20.00 g (50.83 mmol) of erlotinib was added to 440 ㎖ of a mixture of methyl ethyl ketone and distilled water (10:1, v/v) and heated to 30 to 35 ℃ to give a complete solution. 5.15 ㎖ (61.00 mmol) of conc. HCl was added dropwise, and the reaction solution was stirred strongly.
The light yellow crystalline solid formed was filtered and dried under vacuum at 60 ℃ for 20 hours to give 20.35 g of the target compound. The yield was 93.13%.
Experimental Example 1: X-ray structure analysis of crystalline erlotinib dichloroacetate
As shown in Figs. 1, 3, 5 and 7, the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II), erlotinib dichloroacetate (crystalline form III) and erlotinib dichloroacetate hydrate (crystalline form IV) obtained in Examples 1, 6, 7 and 8, respectively, have distinctively characteristic peaks in the X-ray powder diffraction (XRPD) patterns. The observed characteristic peaks shown in the XRPD patterns of Figs. 1, 3, 5 and 7 are listed in Tables 1, 2, 3 and 4, respectively, wherein ‘2θ’ is diffraction angle, ‘d’ is interplanar spacing, and 'I/I0' is relative intensity of the peak.
Table 1
2θ | d | I/I0 | 2θ | d | I/I0 |
6.6120 | 13.36837 | 100 | 23.8402 | 3.73249 | 8.94 |
9.2866 | 9.52336 | 11.50 | 25.0289 | 3.55786 | 6.55 |
13.1025 | 6.75718 | 13.70 | 26.1716 | 3.40505 | 60.18 |
13.5029 | 6.55766 | 6.94 | 26.4245 | 3.37303 | 42.80 |
14.9108 | 5.94152 | 12.62 | 26.9752 | 3.30541 | 20.37 |
16.6186 | 5.33459 | 8.38 | 28.1519 | 3.16987 | 15.92 |
17.6684 | 5.01991 | 7.92 | 28.5382 | 3.12784 | 10.93 |
18.5228 | 4.79025 | 29.90 | 29.3902 | 3.03907 | 5.72 |
19.1765 | 4.62841 | 16.39 | 29.8875 | 2.98963 | 6.84 |
20.0659 | 4.42521 | 14.91 | 31.3903 | 2.84984 | 4.44 |
20.6721 | 4.29680 | 25.87 | 32.6335 | 2.74406 | 5.58 |
21.0734 | 4.21587 | 23.26 | 34.4562 | 2.60297 | 4.18 |
22.5931 | 3.93563 | 37.41 | 35.5362 | 2.52629 | 8.14 |
22.9363 | 3.87750 | 12.02 | 36.6405 | 2.45265 | 3.40 |
Table 2
2θ | d | I/I0 | 2θ | d | I/I0 |
6.5723 | 13.44905 | 100 | 21.6049 | 4.11334 | 20.44 |
7.9780 | 11.08229 | 22.71 | 22.8776 | 3.88732 | 19.63 |
12.9565 | 6.83295 | 22.60 | 23.3969 | 3.80220 | 16.84 |
14.7426 | 6.00891 | 4.80 | 25.9535 | 3.43316 | 35.75 |
15.9316 | 5.56305 | 20.73 | 26.4644 | 3.36804 | 19.30 |
16.7804 | 5.28352 | 32.21 | 27.0396 | 3.29768 | 18.11 |
20.4133 | 4.35069 | 14.88 | 31.0649 | 2.87895 | 12.50 |
20.8314 | 4.26430 | 15.54 |
Table 3
2θ | d | I/I0 | 2θ | d | I/I0 |
7.6210 | 11.60061 | 100 | 26.6368 | 3.34663 | 17.19 |
8.9437 | 9.88775 | 9.05 | 27.8625 | 3.20213 | 6.21 |
11.8985 | 7.43805 | 2.95 | 28.3160 | 3.15187 | 7.79 |
15.0768 | 5.87648 | 6.93 | 29.0865 | 3.07011 | 12.44 |
16.7493 | 5.29325 | 8.94 | 29.6563 | 3.01241 | 4.61 |
17.7167 | 5.00633 | 15.77 | 31.3090 | 2.85706 | 3.08 |
18.1769 | 4.88061 | 19.45 | 32.0511 | 2.79258 | 3.81 |
18.5364 | 4.78676 | 22.28 | 33.1538 | 2.70218 | 4.45 |
21.7141 | 4.09291 | 32.39 | 35.8578 | 2.50437 | 3.21 |
22.6546 | 3.92507 | 39.94 | 36.5906 | 2.45588 | 1.50 |
23.1850 | 3.83647 | 31.59 | 37.2175 | 2.41594 | 2.34 |
23.7956 | 3.73938 | 12.70 | 38.4084 | 2.34373 | 2.21 |
25.0373 | 3.55668 | 8.74 | 39.0321 | 2.30770 | 1.73 |
25.6646 | 3.47115 | 4.98 |
Table 4
2θ | d | I/I0 | 2θ | d | I/I0 |
7.1663 | 12.33567 | 100 | 25.8875 | 3.44177 | 11.6 |
9.0533 | 9.76826 | 30.49 | 26.2819 | 3.39101 | 7.38 |
11.0797 | 7.98584 | 4.46 | 27.0126 | 3.30092 | 25.58 |
11.7158 | 7.55364 | 4.38 | 27.9333 | 3.19417 | 13.27 |
14.5691 | 6.08006 | 21.25 | 29.0344 | 3.07549 | 17.48 |
15.7063 | 5.64232 | 8.19 | 30.4149 | 2.93898 | 6.71 |
16.2238 | 5.46351 | 9.28 | 31.1529 | 2.87102 | 8.95 |
16.9713 | 5.2245 | 11.35 | 31.5744 | 2.83365 | 5.58 |
17.9656 | 4.93754 | 31.02 | 32.0424 | 2.79332 | 12.11 |
18.4106 | 4.81918 | 4.88 | 32.8977 | 2.72262 | 12.58 |
20.0913 | 4.41967 | 19.03 | 34.1307 | 2.62704 | 5.99 |
20.9354 | 4.24335 | 28.81 | 34.8104 | 2.57729 | 7.06 |
21.72 | 4.09181 | 8.09 | 35.608 | 2.52136 | 5.94 |
23.6511 | 3.7619 | 28.27 | 36.2294 | 2.47953 | 5.75 |
24.6313 | 3.61438 | 5.65 | 38.571 | 2.33422 | 0.25 |
Experimental Example 2: Moisture and thermal stability test
The moisture and thermal stability of an active ingredient in a pharmaceutical composition is an important factor on the perspective of the production process and long-term storage of the pharmaceutical composition. Thus, the moisture and thermal stabilities of the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II), erlotinib dichloroacetate (crystalline form III) and erlotinib dichloroacetate hydrate (crystalline form IV) respectively obtained in Examples 1, 6, 7 and 8, and the erlotinib hydrochloride (crystalline form B) obtained in Comparative Example 1 were measured.
Particularly, each erlotinib acid addition salt was stored in a sealed state under an accelerated condition (a temperature of 40 ℃ and a relative humidity of 75 %), and after 0 (zero), 3, 7, 14 and 28 days, the remaining rate of the active ingredient was analyzed with high performance liquid chromatography (HPLC). The results are listed in Table 5.
Table 5
Salts | Initial | 3 days | 7 | 14 days | 28 days |
Erlotinib hydrochloride (crystalline form B) | 100 | 100.1 | 100.1 | 100.0 | 100.0 |
Erlotinib dichloroacetate (crystalline form I) | 100 | 100.1 | 100.0 | 100.0 | 100.1 |
Erlotinib dichloroacetate (crystalline form II) | 100 | 100.0 | 100.0 | 100.0 | 100.0 |
Erlotinib dichloroacetate (crystalline form III) | 100 | 100.1 | 100.0 | 100.0 | 100.0 |
Erlotinib dichloroacetate (crystalline form IV) | 100 | 100.0 | 100.0 | 100.0 | 99.9 |
As shown in Table 5, the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II), erlotinib dichloroacetate (crystalline form III) and erlotinib dichloroacetate hydrate (crystalline form IV) showed the same level of good stability even when exposed to the accelerated condition for 28 days, as compared with the known erlotinib hydrochloride (crystalline form B). Such a result suggests that the erlotinib dichloroacetate of the present invention has good chemical stability to be effectively used for preparing a pharmaceutical composition.
Experimental Example 3: Hygroscopicity test
The hygroscopicities of the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II), erlotinib dichloroacetate (crystalline form III) and erlotinib dichloroacetate hydrate (crystalline form IV) respectively obtained in Examples 1, 6, 7 and 8 were compared with that of the known erlotinib hydrochloride (crystalline form B) obtained in Comparative Example 1.
Each compound was exposed to the condition of a temperature of 40 ℃ and a relative humidity of 75 % for 2 hours, 8 hours, 24 hours and 3 days, and then the amount of moisture contained in the compound was measured with Karl-Fischer titrator. The percentage amounts (weight %) of moisture contained in the active ingredients are listed in Table 6.
Table 6
Salts | Initial | 2 | 8 hours | 24 | 3 days |
Erlotinib hydrochloride (crystalline form B) | 0.27 | 0.38 | 0.27 | 0.33 | 0.33 |
Erlotinib dichloroacetate (crystalline form I) | 0.50 | 0.35 | 0.63 | 0.81 | 0.87 |
Erlotinib dichloroacetate (crystalline form II) | 2.13 | 1.37 | 1.24 | 0.95 | 0.70 |
Erlotinib dichloroacetate (crystalline form III) | 0.42 | 0.32 | 0.26 | 0.28 | 0.39 |
Erlotinib dichloroacetate (crystalline form IV) | 3.09 | 7.64 | 7.55 | 7.73 | 7.61 |
As shown in Table 6, the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II) and erlotinib dichloroacetate (crystalline form III) showed similar non-hygroscopicity even when exposed to the high humidity condition, as compared with the known erlotinib hydrochloride (crystalline form B). Such a result suggests that the erlotinib dichloroacetate (crystalline form I), erlotinib dichloroacetate (crystalline form II) and erlotinib dichloroacetate (crystalline form III) have good moisture stability to be effectively used for preparing a pharmaceutical composition.
Experimental Example 4: Cytotoxicity test (MTT assay)
Human lung cancer NCI-H460 cells and colon cancer SW620 cells were seeded to a 94-well plate in 2.5 x 104 cells/㎖ and cultured for 24 hours, respectively. Each sample was seeded to 4 wells and cultured (n=4).
After 24 hours each of the erlotinib dichloroacetate (crystalline form I), erlotinib hydrochloride (crystalline form B) and dichloroacetic acid was dissolved in dimethylsulfoxide (DMSO) to prepare 10 mM solution, and then 3 μM, 1 μM, 0.3 μM and 0.1 μM solutions were respectively prepared using serum free medium. 100 ㎕ of each prepared solution was seeded to the wells and incubated at 37 ℃ for 48 hours.
20 ㎕ of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each sample and cultured for 2 hours. The absorbance was measured at 510 nm using enzyme-linked immunosorbent assay (ELISA). The MTT was used after dissolving it in phosphate buffered saline (PBS) in 5 mg/ml and filtering the resulting solution.
Control shows the absorbance that was measured for serum free medium containing no drug. The absorbance values for the cells respectively treated with erlotinib dichloroacetate, erlotinib hydrochloride and dichloroacetic acid were measured and the mean of four values was calculated, as the results (%) are represented in Figs. 9 and 10.
The absorbance values for the human lung cancer NCI-H460 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the erlotinib dichloroacetate were 68.27%, 71.08%, 79.08% and 82.12%, respectively, based on 100% of the absorbance value for the control.
Meanwhile, the absorbance values for the NCI-H460 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the erlotinib hydrochloride were 94.04%, 96.76%, 101.72% and 102.49%, respectively. Moreover, the absorbance values for the NCI-H460 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the dichloroacetic acid were 83.99%, 85.04%, 86.76% and 88.08%, respectively.
The above experimental results show that the erlotinib dichloroacetate of the present invention has more potent anti-cancer effects, as compared with erlotinib (erlotinib hydrochloride) or dichloroacetic acid, and generates strong synergy between erlotinib and dichloroacetic acid.
The absorbance values for the colon cancer SW620 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the erlotinib dichloroacetate were 75.54%, 81.14%, 91.65% and 96.26%, respectively, based on 100% of the absorbance value for the control.
Meanwhile, the absorbance values for the SW620 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the erlotinib hydrochloride were 97.14%, 97.24%, 98.81% and 103.11%, respectively. Moreover, the absorbance values for the SW620 cells which were treated with 3 μM, 1 μM, 0.3 μM and 0.1 μM of the dichloroacetic acid were 99.78%, 101.02%, 100.01% and 104.01%, respectively.
The above experimental results show that the erlotinib dichloroacetate of the present invention has more potent anti-cancer effects, as compared with erlotinib (erlotinib hydrochloride) or dichloroacetic acid, and generates strong synergy between erlotinib and dichloroacetic acid.
Consequently, the erlotinib dichloroacetate of the present invention has stronger anti-cancer effects than the erlotinib hydrochloride and generates synergy by the addition of dichloroacetic acid.
Claims (8)
- The erlotinib dichloroacetate of Claim 1, wherein the erlotinib dichloroacetate is a crystalline form.
- The erlotinib dichloroacetate of Claim 1, wherein the erlotinib dichloroacetate is a crystalline form showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 6.6±0.2, 9.3±0.2, 13.1±0.2, 14.9±0.2, 18.5±0.2, 19.2±0.2, 20.1±0.2, 20.7±0.2, 21.1±0.2, 22.6±0.2, 22.9±0.2, 26.2±0.2, 26.4±0.2, 27.0±0.2, 28.2±0.2, and 28.5±0.2.
- The erlotinib dichloroacetate of Claim 1, wherein the erlotinib dichloroacetate is a crystalline form showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 6.6±0.2, 8.0±0.2, 13.0±0.2, 16.0±0.2, 16.8±0.2, 20.4±0.2, 20.8±0.2, 21.6±0.2, 22.9±0.2, 23.4±0.2, 26.0±0.2, 26.5±0.2, 27.0±0.2, and 31.1±0.2.
- The erlotinib dichloroacetate of Claim 1, wherein the erlotinib dichloroacetate is a crystalline form showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 7.6±0.2, 17.7±0.2, 18.2±0.2, 18.5±0.2, 21.7±0.2, 22.7±0.2, 23.2±0.2, 23.8±0.2, 26.6±0.2, and 29.1±0.2.
- The erlotinib dichloroacetate of Claim 1, wherein the erlotinib dichloroacetate is a crystalline erlotinib dichloroacetate hydrate showing an X-ray powder diffraction (XRPD) pattern characterized by peaks having I/Io values of at least 10% (I is the intensity of each peak; Io is the intensity of the highest peak) at diffraction angles (2θ) of 7.2±0.2, 9.1±0.2, 14.6±0.2, 17.0±0.2, 18.0±0.2, 20.1±0.2, 20.9±0.2, 23.7±0.2, 25.9±0.2, 27.0±0.2, 28.0±0.2, 29.0±0.2, 32.0±0.2, and 32.9±0.2.
- An anti-cancer agent comprising the erlotinib dichloroacetate of any one of Claims 1 to 6 with a pharmaceutically acceptable carrier.
- The anti-cancer agent of Claim 7, wherein the anti-cancer agent is used for treating non-small cell lung cancer (NSCLC) or pancreatic cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0068603 | 2010-07-15 | ||
KR1020100068603A KR101208956B1 (en) | 2010-07-15 | 2010-07-15 | Erlotinib dichloroacetate and anti-cancer agent comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012008711A2 true WO2012008711A2 (en) | 2012-01-19 |
WO2012008711A3 WO2012008711A3 (en) | 2012-05-24 |
Family
ID=45469896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/004985 WO2012008711A2 (en) | 2010-07-15 | 2011-07-07 | Erlotinib dichloroacetate and anti-cancer agent comprising the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101208956B1 (en) |
WO (1) | WO2012008711A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102584719A (en) * | 2012-02-02 | 2012-07-18 | 瑞阳制药有限公司 | Preparing technology of erlotinib hydrochloride |
WO2013109142A1 (en) * | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
EP3842042A4 (en) * | 2018-08-22 | 2022-08-17 | Metafines.Co.Ltd. | Pharmaceutical composition for treating cancer comprising metal ion-bound ionic compound |
RU2780016C1 (en) * | 2018-08-22 | 2022-09-19 | Метафинес.Ко.Лтд. | Pharmaceutical composition for cancer treatment, containing ionic compound related to metal ion |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900221B1 (en) * | 1999-11-11 | 2005-05-31 | Osi Pharmaceuticals, Inc. | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
US20080058355A1 (en) * | 2006-07-28 | 2008-03-06 | Westheim Raymond J H | Crystalline erlotinib |
US20100130741A1 (en) * | 2007-07-11 | 2010-05-27 | Hetero Drugs Limited | Process for erlotinib hydrochloride |
-
2010
- 2010-07-15 KR KR1020100068603A patent/KR101208956B1/en active IP Right Grant
-
2011
- 2011-07-07 WO PCT/KR2011/004985 patent/WO2012008711A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900221B1 (en) * | 1999-11-11 | 2005-05-31 | Osi Pharmaceuticals, Inc. | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
US20080058355A1 (en) * | 2006-07-28 | 2008-03-06 | Westheim Raymond J H | Crystalline erlotinib |
US20100130741A1 (en) * | 2007-07-11 | 2010-05-27 | Hetero Drugs Limited | Process for erlotinib hydrochloride |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013109142A1 (en) * | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
CN102584719A (en) * | 2012-02-02 | 2012-07-18 | 瑞阳制药有限公司 | Preparing technology of erlotinib hydrochloride |
WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
EP3842042A4 (en) * | 2018-08-22 | 2022-08-17 | Metafines.Co.Ltd. | Pharmaceutical composition for treating cancer comprising metal ion-bound ionic compound |
RU2780016C1 (en) * | 2018-08-22 | 2022-09-19 | Метафинес.Ко.Лтд. | Pharmaceutical composition for cancer treatment, containing ionic compound related to metal ion |
AU2019324286B2 (en) * | 2018-08-22 | 2023-02-02 | Metafines.Co.Ltd. | Pharmaceutical composition for treating cancer comprising metal ion-bound ionic compound |
Also Published As
Publication number | Publication date |
---|---|
KR101208956B1 (en) | 2012-12-06 |
KR20120007848A (en) | 2012-01-25 |
WO2012008711A3 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6410582B1 (en) | Thienylazolylalcoxyethanamines, their preparation and their application as medicaments | |
PT84896B (en) | METHOD FOR THE PREPARATION OF DISTAMICINE ANALOGS WITH ANTINEOPLASTIC AND ANTI-VIRAL ACTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ZA200500030B (en) | MCH1r antagonists. | |
WO2011081408A2 (en) | Imatinib dichloroacetate and anti-cancer agent comprising the same | |
BR112012012529B1 (en) | INDOL COMPOUND, PHARMACEUTICAL COMPOSITION, INHIBITORS AND AGENTS INCLUDING SUCH COMPOUND AND ITS USES | |
WO2020067735A1 (en) | 3-azabicyclo[3,1,1]heptane derivative and pharmaceutical composition comprising same | |
BRPI0609265A2 (en) | substituted aminoalkyl and amidoalkyl benzopyran derivatives | |
WO2016117814A2 (en) | Novel crystal form of benzimidazole derivative and preparation method thereof | |
WO2012008711A2 (en) | Erlotinib dichloroacetate and anti-cancer agent comprising the same | |
WO2020040467A1 (en) | Crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6h)-one hydrochloride and method for preparing same | |
US20230219935A1 (en) | 4-(n-methyl) aminopiperidine myricetin derivative containing dithiocarbamate, preparation method and application | |
KR101435496B1 (en) | Benzimidazole derivatives as mitochondrial function modulators | |
US20080262029A1 (en) | Acid and Base Salt Forms of Gaboxadol | |
EP3418277A1 (en) | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | |
KR910009934B1 (en) | Carbamoyl-2-pyrrolidinone compounds | |
WO2009119980A2 (en) | Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same | |
WO2010151008A2 (en) | Piperazine dithioctate and pharmaceutical composition comprising the same | |
EP0347672B1 (en) | Benzazepine derivatives | |
KR101165483B1 (en) | 2h- or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof | |
EP4004013A1 (en) | Dinucleotide compounds for treating cancers and medical uses thereof | |
WO2019245194A1 (en) | Novel compound for treating naprt negative cancer and composition comprising same | |
WO2018062837A1 (en) | Chalcone derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising same as effective ingredient for preventing or treating disease caused by reduction in mitochondrial oxygen consumption rate | |
WO2021133129A2 (en) | Novel dihydroindeno[1,2-c]pyrazole-3-carboxamide derivative and pharmaceutical composition for prevention or treatment of neurodevelopmental disorders or neurodegenerative diseases, comprising same | |
WO2024072108A1 (en) | Novel crystalline form of enavogliflozin, and preparation method therefor | |
KR102613509B1 (en) | Macrocyclic pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for the prevention or treatment of neurodegenerative disease containing the same as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11806996 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11806996 Country of ref document: EP Kind code of ref document: A2 |